Impact of hydroxyurea on clinical events in the BABY HUG trial

Courtney D. Thornburg, Beatrice A. Files, Zhaoyu Luo, Scott T. Miller, Ram Kalpatthi, Rathi Iyer, Phillip Seaman, Jeffrey Lebensburger, Ofelia A Alvarez, Bruce Thompson, Russell E. Ware, Winfred C. Wang

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was a phase 3 multicenter, randomized, double-blind, placebocontrolled clinical trial of hydroxyurea in infants (beginning at 9-18 months of age) with sickle cell anemia. An important secondary objective of this study was to compare clinical events between the hydroxyurea and placebo groups. One hundred and ninetythree subjects were randomized to hydroxyurea (20 mg/kg/d) or placebo; there were 374 patient-years of on-study observation. Hydroxyurea was associated with statistically significantly lower rates of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants who were asymptomatic at enrollment had less dactylitis as well as fewer hospitalizations and transfusions if treated with hydroxyurea. Despite expected mild myelosuppression, hydroxyurea was not associated with an increased risk of bacteremia or serious infection. These data provide important safety and efficacy information for clinicians considering hydroxyurea therapy for very young children with sickle cell anemia. This clinical trial is registered with the National Institutes of Health (NCT00006400, www.clinicaltrials. gov).

Original languageEnglish
Pages (from-to)4304-4310
Number of pages7
JournalBlood
Volume120
Issue number22
DOIs
StatePublished - Nov 22 2012

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Hospitalization
Acute Chest Syndrome
Placebos
Clinical Trials
Phase III Clinical Trials
Pediatrics
National Institutes of Health (U.S.)
Bacteremia
Observation
Health
Safety
Pain
Infection

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Thornburg, C. D., Files, B. A., Luo, Z., Miller, S. T., Kalpatthi, R., Iyer, R., ... Wang, W. C. (2012). Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood, 120(22), 4304-4310. https://doi.org/10.1182/blood-2012-03-419879

Impact of hydroxyurea on clinical events in the BABY HUG trial. / Thornburg, Courtney D.; Files, Beatrice A.; Luo, Zhaoyu; Miller, Scott T.; Kalpatthi, Ram; Iyer, Rathi; Seaman, Phillip; Lebensburger, Jeffrey; Alvarez, Ofelia A; Thompson, Bruce; Ware, Russell E.; Wang, Winfred C.

In: Blood, Vol. 120, No. 22, 22.11.2012, p. 4304-4310.

Research output: Contribution to journalArticle

Thornburg, CD, Files, BA, Luo, Z, Miller, ST, Kalpatthi, R, Iyer, R, Seaman, P, Lebensburger, J, Alvarez, OA, Thompson, B, Ware, RE & Wang, WC 2012, 'Impact of hydroxyurea on clinical events in the BABY HUG trial', Blood, vol. 120, no. 22, pp. 4304-4310. https://doi.org/10.1182/blood-2012-03-419879
Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012 Nov 22;120(22):4304-4310. https://doi.org/10.1182/blood-2012-03-419879
Thornburg, Courtney D. ; Files, Beatrice A. ; Luo, Zhaoyu ; Miller, Scott T. ; Kalpatthi, Ram ; Iyer, Rathi ; Seaman, Phillip ; Lebensburger, Jeffrey ; Alvarez, Ofelia A ; Thompson, Bruce ; Ware, Russell E. ; Wang, Winfred C. / Impact of hydroxyurea on clinical events in the BABY HUG trial. In: Blood. 2012 ; Vol. 120, No. 22. pp. 4304-4310.
@article{981e869b22dc479ba638fa5f41712267,
title = "Impact of hydroxyurea on clinical events in the BABY HUG trial",
abstract = "The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was a phase 3 multicenter, randomized, double-blind, placebocontrolled clinical trial of hydroxyurea in infants (beginning at 9-18 months of age) with sickle cell anemia. An important secondary objective of this study was to compare clinical events between the hydroxyurea and placebo groups. One hundred and ninetythree subjects were randomized to hydroxyurea (20 mg/kg/d) or placebo; there were 374 patient-years of on-study observation. Hydroxyurea was associated with statistically significantly lower rates of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants who were asymptomatic at enrollment had less dactylitis as well as fewer hospitalizations and transfusions if treated with hydroxyurea. Despite expected mild myelosuppression, hydroxyurea was not associated with an increased risk of bacteremia or serious infection. These data provide important safety and efficacy information for clinicians considering hydroxyurea therapy for very young children with sickle cell anemia. This clinical trial is registered with the National Institutes of Health (NCT00006400, www.clinicaltrials. gov).",
author = "Thornburg, {Courtney D.} and Files, {Beatrice A.} and Zhaoyu Luo and Miller, {Scott T.} and Ram Kalpatthi and Rathi Iyer and Phillip Seaman and Jeffrey Lebensburger and Alvarez, {Ofelia A} and Bruce Thompson and Ware, {Russell E.} and Wang, {Winfred C.}",
year = "2012",
month = "11",
day = "22",
doi = "10.1182/blood-2012-03-419879",
language = "English",
volume = "120",
pages = "4304--4310",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - Impact of hydroxyurea on clinical events in the BABY HUG trial

AU - Thornburg, Courtney D.

AU - Files, Beatrice A.

AU - Luo, Zhaoyu

AU - Miller, Scott T.

AU - Kalpatthi, Ram

AU - Iyer, Rathi

AU - Seaman, Phillip

AU - Lebensburger, Jeffrey

AU - Alvarez, Ofelia A

AU - Thompson, Bruce

AU - Ware, Russell E.

AU - Wang, Winfred C.

PY - 2012/11/22

Y1 - 2012/11/22

N2 - The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was a phase 3 multicenter, randomized, double-blind, placebocontrolled clinical trial of hydroxyurea in infants (beginning at 9-18 months of age) with sickle cell anemia. An important secondary objective of this study was to compare clinical events between the hydroxyurea and placebo groups. One hundred and ninetythree subjects were randomized to hydroxyurea (20 mg/kg/d) or placebo; there were 374 patient-years of on-study observation. Hydroxyurea was associated with statistically significantly lower rates of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants who were asymptomatic at enrollment had less dactylitis as well as fewer hospitalizations and transfusions if treated with hydroxyurea. Despite expected mild myelosuppression, hydroxyurea was not associated with an increased risk of bacteremia or serious infection. These data provide important safety and efficacy information for clinicians considering hydroxyurea therapy for very young children with sickle cell anemia. This clinical trial is registered with the National Institutes of Health (NCT00006400, www.clinicaltrials. gov).

AB - The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was a phase 3 multicenter, randomized, double-blind, placebocontrolled clinical trial of hydroxyurea in infants (beginning at 9-18 months of age) with sickle cell anemia. An important secondary objective of this study was to compare clinical events between the hydroxyurea and placebo groups. One hundred and ninetythree subjects were randomized to hydroxyurea (20 mg/kg/d) or placebo; there were 374 patient-years of on-study observation. Hydroxyurea was associated with statistically significantly lower rates of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants who were asymptomatic at enrollment had less dactylitis as well as fewer hospitalizations and transfusions if treated with hydroxyurea. Despite expected mild myelosuppression, hydroxyurea was not associated with an increased risk of bacteremia or serious infection. These data provide important safety and efficacy information for clinicians considering hydroxyurea therapy for very young children with sickle cell anemia. This clinical trial is registered with the National Institutes of Health (NCT00006400, www.clinicaltrials. gov).

UR - http://www.scopus.com/inward/record.url?scp=84869803950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869803950&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-03-419879

DO - 10.1182/blood-2012-03-419879

M3 - Article

C2 - 22915643

AN - SCOPUS:84869803950

VL - 120

SP - 4304

EP - 4310

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -